Member Info for Sheepy57

Finally... hope it'll stay on course.

£5 reached and now some pull back.

I always knew there would be something magic about it here. It's a beanstock. Hope is that PURP will completaly change the way we buy and sell houses, make it cheaper and easier. High street agents will be victims of the change of course. Soon will start it's offer across the pond and... we will see. Have a happy holiday.

ToTheFuture, there is still at least one unconvinced broker valuing a share at 94p. Did I mention Jefferies International? Since the float they have always said PURP would have underperformed.

Oh dear, if I had spare cash I would start buying again. As I'm in preparation for a holiday and my budget's so tight that I can't grab any more shares without selling somewhere else.

Vertex Pharmaceuticals Inc. on Tuesday released clinical findings showing its new approach to combating cystic fibrosis substantially improved lung function in patients, lifting hopes for a treatment that could be used by about 68,000 people worldwide — including 24,000 who don’t respond to any existing medicines. The results prompted Boston-based Vertex to say it plans to launch one or two late-stage clinical trials of the biotech’s three-drug combination in the first half of next year. VRTX price popped up today over 20%.

It's nothing new! nDreams was in Merc's portfolio at the time they floated on AIM. The company's first involvement with nDreams was in 2013, and various funding rounds have brought its direct shareholding to 45.6% as of this month. (Year ago it was already 40%)

Oldjaybee, you had in mind £10 or 1000p not £1, hadn't you?

Ton of patience may be needed here. At least it started march upward. GLA

Nice buy 1407489 shares @400p (09.20hrs)

http://www.barrons.com/articles/biotech-2q17-its-mostly-all-gravy-1499953599 "SunTrust Robinson Humphrey's biotechnology team expects Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Celgene (CELG), Clovis Oncology (CLVS), Incyte (INCY), Sarepta Pharmaceutical (SRPT), and Tesaro (TSRO) to beat consensus revenue estimates. Regeneron (REGN) and Seattle Genetics (SGEN), on the other hand, "are likely to report in-line results." Another rosy prediction for the sector- http://www.investopedia.com/news/bull-flag-forming-biotech-etf/

I think it’s a good business that could be worth more in the future and a long-term view may be needed here. If they are successful in the US market, which is much bigger than UK, the share price will go up.

Automation Anywhere is not on that list. Says a lot.

Preliminary results for the year ended 31 March 2017 A year of positive progress across the Group's investing activities Mercia Technologies PLC (AIM: MERC, 'Mercia' or 'the Group'), the national investment group focused on the creation/identification, funding and scaling of innovative technology businesses with high growth potential from the UK regions, is pleased to announce its preliminary results for the year ended 31 March 2017. Group and portfolio highlights £11.7million net invested in 15 portfolio companies during the year, including four new Emerging Stars Concepta was admitted to AIM in July 2016. Its board has recently been strengthened by the appointment of Philips UK CEO, Neil Mesher, as a non-executive director The fair value of nDreams has increased significantly following a successful syndicated investment round in November 2016 Allinea Software was sold to ARM in December 2016 providing an 88.4% uplift on the Group's direct investment cost The integration of Enterprise Ventures Group Ltd ('Enterprise Ventures') was successfully completed, creating a critical mass of more than 65 investment professionals and support staff across six locations within the UK regions A sustainable funnel of new investment opportunities is now built following significant new fund mandate wins which scale the Group's fund management business from circa £220.0million to circa £336.5million of funds under management The successful Placing which raised £40.0million in February 2017 has provided additional balance sheet capital which is predominantly to be used to scale the Group's direct investment portfolio as it continues to develop Financial highlights Direct investment portfolio value up by £13.9million to £52.0million (2016: £38.1million) Net fair value gains £4.3million (2016: £0.9million) Realised gains £0.8million (2016: £nil) Net assets £121.4million (2016: £80.0million) Net assets per share increased to 40.4 pence (2016: 37.5 pence) Cash and short-term liquidity investments £63.8million (2016: £30.9million) Revenue increased to £6.7million (2016: £1.8million) Pre-exceptional operating profit £1.9million (2016: £1.7million loss) Exceptional item - 50% of the anticipated Enterprise Ventures deferred contingent consideration has been accounted for as the £80.0million net new funds target has already been achieved half way through the deferred consideration period: £1.1million (2016: £0.4million Enterprise Ventures acquisition costs) Profit for the financial year £1.0million (2016: £1.7million loss) Post year end £4.6million invested post year end, including £1.5million into Impression Technologies, £0.8million into Edge Case Games, £0.8million into Warwick Audio Technologies and £0.5million into Oxford Genetics, with the increased investm

Following modest gains in home sales in 2016, California’s housing market will post a nominal increase in 2017, as supply shortages and affordability constraints hamper market activity. The C.A.R. forecast sees a slight increase in existing home sales of 0.8 percent next year to reach 419,600 units. http://www.car.org/marketdata/marketforecast/

@Resipsa It might've been proactiveinvestors. http://www.proactiveinvestors.co.uk/columns/the-naked-fund-manager/27180/purplebricks-us-expansion-how-big-is-the-opportunity-27180.html

It may look like the share price outpaced the profits but I think that many are ready to pay today's price for tomorrow's success.

Terrace you should've short the stock long time ago. It was at low 100p-ish when you said it is worth no more than 30p. Or it wasn't you?

Final results for the year ended 30 April 2017 UK expectations upgraded, Australia on track, US beckons Purplebricks Group plc (AIM: PURP) ("Purplebricks"), the hybrid estate agent providing a new way to buy, sell or let property, announces its final results for the year ended 30 April 2017. Financial highlights UK Australia US Total UK and Total Year ended 30 April, £m 2017 2017 2017 2017 2016 Revenue 43.2 3.5 - 46.7 18.6 Gross profit 24.2 1.6 - 25.8 10.6 Marketing (14.4) (3.8) - (18.2) (12.9) Operating profit/(loss) 0.2 (6.1) (0.1) (6.0) (11.9) Adjusted EBITDA (1) 1.7 (6.1) (0.1) (4.5) (9.7) Business Highlights · Group revenue up 151% to £46.7m (FY16: £18.6m) · UK revenue up 132% to £43.2m (FY16: £18.6m) · Ahead of recruitment plan; number of UK Local Property Experts rose 118% to 448 as of April 2017 · UK business reports first full year operating profit and adjusted EBITDA of £1.7m (FY16: loss £9.7m) · Average income per instruction for the UK up 14.8% to £1,035 (£1,088 for the Group) · Sold and completed on over £5.8bn of UK property (further £3.69bn in pipeline SSTC) · Online market share increased to 72% (from 62%) whilst online growing as a share of total market · Sale agreed in the UK every 9 minutes 24/7 · Website visits increased to over 2.5m per month · Most positively reviewed agent on Trustpilot in the UK with over 20,000 reviews · Successful launch in Australia; ahead of UK at same stage of development in terms of listings, sales, revenue, LPEs and Trustpilot · Raised £50m in March 2017 to launch in the US, a $70bn market, starting with California · Strong Balance Sheet, with net cash of £71.3m Commenting on the results, Michael Bruce, Group Chief Executive, said: "This has been a very successful year in the early development of the Purplebricks model and brand. We have materially grown our national footprint and have built a growing brand awareness and reputation for delivering customers a more convenient, transparent and cost effective service. In tandem with our growth we have invested in the business and strengthened the management team. This has allowed us to significantly grow our number of positive reviews on the independent review site Trustpilot (currently with over 20,000). We have retained our rating of excellent. Purplebricks is now in a strong position to become the no.1 estate agent in the UK for both listings and sales. With the UK business now in profit it is encouraging to see Australia following a similar growth trajectory. Just e

CEO is still a human and want to enjoy life with his hard earned money. He just sold 10% of his stake.